NeOnc Technologies Holdings is trading at $3.95, down -6.32%, amid substantial recent volatility following positive Phase 2a NEO100 results.

  • The stock opened the August 17, 2026 session after a 31.46% gain to $4.22 on August 14.
  • No new August 17 company-specific catalyst was identified; the latest company updates remain dated August 12.
  • The study met its primary endpoint, and management plans an FDA Type B meeting.